BioSpace News Archive

Calyx , the eClinical and Regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, today announced the availability of Calyx CTMS v15.0

- COVID-19 vaccine candidate: CVnCoV in final stage of clinical development and believed to be well on track to provide data for conditional approval based on EMA rolling submission

ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced the time of its first quarter 2021 earnings release and conference call.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Cluster headache pathophysiology — insights from current and emerging treatments,” by Drs. Diana Wei and Peter Goadsby in Nature Reviews: Neurology.1

Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a Company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, announced today that it has entered into a Master Service Agreement with a Contract Development & Manufacturing Organization (CDMO),

Presentations include data highlighting real-world use of RECELL in combination with complementary treatments, clinical versatility, and cost effectiveness of RECELL to advance patient care

Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”)

AltruBio Inc., a clinical stage biotech company, has announced the completion of a $63 million Series A financing round.

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of April 2021, which is payable on May 17, 2021 to shareholders of record at the close of business on April 30, 2021.

Urges Stockholders to Vote the WHITEProxy Card “FOR ALL” of Adverum’s Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed Tuckson, M.D. and Tom Woiwode, Ph.D.